Turn Therapeutics Inc. Common Stock

TTRX

Market cap $139M

LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming Founder Blog authored by patient-turned-founder and CEO, Bradley Burnam.

Veteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programs Veteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programs

Six IPOs debuted this week, while two SPACs listed. Thirteen IPOs and five SPACs also submitted initial filings. No traditional IPOs are currently scheduled for the week ahead as the government shutdown continues to mostly pause new issuance.

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing dermatology, wound care, and anti-infective therapies, today announced that it expects its common stock will begin trading on the Nasdaq Global Market under the ticker symbol “TTRX” on October 8, 2025. Copies of the prospectus, when available, may be obtained from Turn Therapeutics, 250 N. Westlake Blvd., Westlake Village, CA 91362. About Turn Therapeutics Tu.